Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2020.12.015Source: DataRank Database

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial is a research paper published in Journal of Thoracic Oncology (2021). On theSindex it has a DataRank of 6.9. It has been cited 471 times, with 100 citing works in its 1-hop citation network.

N/A

6.9DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access471 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02125461

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (33 grants)OA: hybridTopics (11)Linked Datasets (25)DataCite Reuse (25)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 13%Citation Network 87%

Base Score Contribution

0.924

From this paper's citation signal

Citation Network Contribution

6.0

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
Frontiers in Oncology202149 citations9 referencesContributes 0.435
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
Annals of Oncology2021455 citations15 referencesContributes 0.408
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Journal of Clinical Oncology20221,324 citations24 referencesContributes 0.300
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer
Clinical Lung Cancer202219 citations13 referencesContributes 0.230
Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab
JAMA Network Open202226 citations19 referencesContributes 0.173

Authors (23)

David Vicente ORCID,Takayasu Kurata ORCID,David Planchard ORCID,Luis Paz‐Ares ORCID,Johan Vansteenkiste ORCID

Live enrichment

PubMed:33476803

NCI NIH HHS

Grant: P30 CA008748

Aeglea BioTherapeutics

AstraZeneca

Bristol-Myers Squibb

Daiichi-Sankyo

Roche

Samsung

Sanofi

Takeda Pharmaceutical Company

AbbVie

Genentech

Merck KGaA

TG Therapeutics

Eli Lilly and Company

Merck

Merck Sharp and Dohme

Varian Medical Systems

National Institute for Health and Care Research

Bayer

EMD Serono

National Institutes of Health

Neos Therapeutics

Novartis

Celgene

Clovis Oncology

F. Hoffmann-La Roche

Manchester Biomedical Research Centre

Astellas Pharma

Boehringer Ingelheim

Elekta

GlaxoSmithKline

Pfizer

Shionogi

Influential Citations

hybridLicense: cc-by-nc-nd

HYBRIDhttps://doi.org/10.1016/j.jtho.2020.12.015

publisherhttps://doi.org/10.1016/j.jtho.2020.12.015

publisherhttps://api.elsevier.com/content/article/PII:S1556086421000228?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1556086421000228?httpAccept=text/plain

repositoryhttps://research.manchester.ac.uk/en/publications/0a54ef95-71fb-4436-ba99-4c1e0eb27520

Fields of Study

Medicine

MeSH Terms

HumansCarcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, MonoclonalChemoradiotherapy

Keywords

PacificOverall SurvivalProgression-free SurvivalLocally Advanced NsclcDurvalumab

Additional file 1 of Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

10.6084/m9.figshare.18482529.v1figshare

Additional file 1 of Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

10.6084/m9.figshare.18482529figshare

Additional file 1 of Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment

10.6084/m9.figshare.20330116.v1figshare

10.6084/m9.figshare.20330116figshare

Additional file 1 of The pilot project of the National Cancer Network in Poland: Assessment of the functioning of the National Cancer Network and results from quality indicators for lung cancer (2019–2021)

10.6084/m9.figshare.20762834.v1figshare

10.6084/m9.figshare.20762834figshare

Additional file 1 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570266.v1figshare

Additional file 1 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570266figshare

Additional file 2 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570269.v1figshare

Additional file 2 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570269figshare

Additional file 3 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570272.v1figshare

Additional file 3 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570272figshare

Additional file 4 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570275.v1figshare

Additional file 4 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570275figshare

Additional file 5 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570278.v1figshare

Additional file 5 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570278figshare

Additional file 6 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570281.v1figshare

Additional file 6 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570281figshare

Additional file 7 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570284.v1figshare

Additional file 7 of Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain

10.6084/m9.figshare.26570284figshare

Related Papers (10)

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

N/A

4.9DataRank · unranked

Journal for ImmunoTherapy of Cancer(2020)

co-cited

10.1136/jitc-2020-001001

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

N/A

1.3DataRank · unranked

New England Journal of Medicine(2018)

co-cited

10.1056/nejmoa1801005

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

N/A

1.3DataRank · unranked

Science(2018)

co-cited

10.1126/science.aan4236

Cancer Statistics, 2021

Top 2%

7.2DataRank

CA: A Cancer Journal for Clinicians(2021)

co-cited

10.3322/caac.21654

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

N/A

1.3DataRank · unranked

Science(2018)

co-cited

10.1126/science.aan3706

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

N/A

1.2DataRank · unranked

Science(2018)

co-cited

10.1126/science.aao3290

TIGIT in cancer immunotherapy

N/A

0.992DataRank · unranked

Journal for ImmunoTherapy of Cancer(2020)

co-cited

10.1136/jitc-2020-000957

Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity

International Journal of Molecular Sciences(2020)

co-cited

10.3390/ijms21218363

Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma

N/A

4.1DataRank · unranked

Nature Communications(2020)

co-cited

10.1038/s41467-020-17175-8

Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials

N/A

2.9DataRank · unranked

Journal for ImmunoTherapy of Cancer(2020)

co-cited

10.1136/jitc-2019-000492

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (23)

Funding (33 grants)

Impact

Open Access

Topics

Linked Datasets (25)

Related Papers (10)